Abstract. Overexpression of HER2 protein and HER2 gene amplification in breast cancer are prognostic factors for the response to specific medical treatments such as trastuzumab, endocrine therapy, and chemotherapy. Whereas HER2 expression and gene amplification are generally examined in tissue sections, we investigated whether specimens from fine needle aspiration cytology (FNAC) are adequate for these analyses. HER2 protein overexpression and HER2 gene amplification were assessed in both FNAC specimens and tissue sections from 58 cases of invasive breast cancer. Immunohistochemistry assay for HER2 protein expression was performed according to the HercepTest protocol, and HER2 gene amplification was examined with the Spot-light CISH (chromogenic in situ hybridization) Detection kit. There was a significant positive correlation between assessments of HER2 protein status in the cytology specimens and tissue sections. The sensitivity, specificity, and accuracy of HER2 gene amplification detection in cytology specimens in relation to those in tissue sections were 84.0% (21/25 cases), 87.9% (29/33 cases), and 86.2% (50/58 cases), respectively. FNAC specimens are suitable for detection of HER2 overexpression and HER2 gene amplification in invasive breast cancer.
Introduction
Overexpression of HER2 protein and HER2 gene amplification in breast cancer are prognostic factors for the response to specific medical treatments such as trastuzumab, endocrine therapy, and chemotherapy (1-7). HER2 gene amplification or HER2 protein overexpression has been identified in 20-30% of human breast cancers (8, 9) . HER2 expression and gene amplification are generally examined in tissue sections; however, it would be beneficial if cytology specimens could be used because the method used to obtain such specimens is minimally invasive. Even in tissue samples obtained by core needle biopsy, it is often too difficult to assess HER2 status because the samples are very small or the cancer cells are crushed. Although some studies of HER2 status in cytology specimens have been reported (10) (11) (12) (13) (14) , assessment of HER2 status in the cytology specimen has not been clearly defined. Moreover, no studies comparing cytology specimens and tissue sections with respect to HER2 expression and HER2 amplification have been reported. Therefore, the goal of the present study was to determine whether fine needle aspiration cytology (FNAC) specimens can be used for the assessment of HER2 gene amplification and HER2 overexpression.
Materials and methods
Patients. The study population consisted of 58 patients who underwent surgery for primary invasive breast cancer at Osaka Medical College (Japan). Patient and tumor characteristics are shown in Table I . The patients comprised 1 man and 57 women who ranged in age from 32-84 years. The tumors included 20 papillotubular carcinomas, 6 solid tubular carcinomas, 31 scirrhous carcinomas, and 1 mucinous carcinoma. During surgery, we used a fine needle to obtain an aspirate from the central part of the resected tumor, and prepared cytology specimens fixed in 95% ethanol. We later prepared sections from formalin-fixed, paraffin-embedded tissue specimens from the same cases. We compared HER2 status in cytology specimens and tissue sections. Histologic type was determined from sections of the central part of the tissue specimens. specimens were reacted with the anti-HER2 polyclonal antibody provided with the HercepTest (A485), then visualized using the Envision method (DakoCytomation). Tissue sections were deparaffinized before antigen retrieval in citrate buffer (pH 6.0) at 95˚C for 40 min, then 20 min at room temperature. Antigen retrieval was not performed for the cytology specimens. Assessment of HER2 protein expression. HER2 protein levels were determined as described in the HercepTest manual (Fig. 1 
Chromogenic in situ hybridization (CISH)
. CISH of tissue sections was done according to the protocol of the Spot-light CISH Detection kit (Zymed Inc.). Sections were deparaffinized, and incubated in a 95˚C water bath for 15 min. Sections were then treated with proteinase K at room temperature for 10 min. Endogenous peroxidase activity was blocked with 3% H 2 O 2 in methanol, and samples were then air dried. Digoxigenin-labeled HER2 probe (15 μl) was applied to the sections, which were then covered with coverslips. Slides were denatured on a hot plate at 80˚C for 3 min, and hybridization was performed overnight (16-24 h) at 37˚C. To remove the coverslips, the slides were soaked in 1X Tris-buffered saline containing 0.1% Tween-20. Slides were then washed with a stringent wash solution at 75˚C for 5 min. Samples were blocked with normal serum, then incubated with mouse anti-digoxigenin and polymerized HRP-anti-mouse antibody for 60 min at room temperature. Binding was visualized with 3,3'-diamino benzidine.
For cytology specimens, a slightly modified protocol was used. Briefly, after enzymatic digestion, cells were re-fixed with 4% paraformaldehyde at room temperature for 15 min. Slides were denatured on a hot plate at 90˚C for 3 min and hybridized overnight at 37˚C. Slides were then washed with a stringent wash solution (1:10 dilution of standard sodium citrate solution) at 50-55˚C for 5 min. All other procedures were as described for tissue sections. Positive controls were included in each staining run. Table I . Clinical characteristics of patients with invasive breast cancer. Table II . HER2 protein overexpression and HER2 gene amplication in tissue sections. Table III . HER2 protein overexpression and HER2 gene amplification in FNAC specimens. Table IV . Comparison of FNAC specimens and tissue sections in IHC assay. 
FNAC, fine needle aspiration cytology; IHC, immunohistochemistry. Table V . HER2 gene amplification score in FNAC specimens and tissue sections. 
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FNAC, fine needle aspiration cytology; Chr17, chromosome 17. Table VI . Comparison between FNAC specimens and tissue sections in the detection of HER2 gene amplification. 
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HER2 gene amplification.
For both tissue sections and FNAC specimens, HER2 amplification was assessed according to the Zymed HER2 CISH Test Interpretation Guide, as shown in Fig. 2 . Briefly, no amplification was defined as ≤5 HER2 signals per nucleus in at least 50% of cancer cells. Amplification was defined as >10 dots or signals or large clusters of HER2 per nucleus in at least 50% of the cancer cells. Scores were assigned as: A, clusters; B, multiple dots; and C, clusters and multiple dots. Low amplification (score D) was defined as 5 to 10 dots (or signals) of HER2 per nucleus in at least 50% of cancer cells. In cases of low HER2 amplification, we used biotin-labeled Spot-light Chromosome 17 Centromeric Probe (Chr17 cen probe ) to confirm that the HER2 signals of the gene were due to HER2 gene amplification rather than polysomy of chromosome 17. When two signals were observed for Chr17 in a nucleus, we considered any extra HER2 dots to be caused by HER2 amplification (Fig. 3) . We examined the correlations between the data from cytology specimens and tissue sections with a 2x2 table for sensitivity, specificity, and accuracy.
Results
HER2 expression.
HER2 protein scores for tissue sections are shown in Table II . Twenty cases had a score of 0, 8 cases had a score of 1+, 9 cases had a score of 2+, and 21 cases had a score of 3+. HER2 protein scores for FNAC specimens are shown in Table III . Twenty-one cases had a score of 0, 4 cases had a score of 1+, 17 cases had a score of 2+, and 16 cases had a score 3+. Assuming that cases with a score of 1+ or 0 are in the same category, as the difference between score 0 and score 1+ is not clinically important, accuracy was 75.9% (44/58 cases) (Table IV) . When histological type was considered, concordance between FNAC samples and tissue sections (assuming cases with a score of 1+ or 0 are in the same category) was 75.0% (15/20 cases) for papillotubular carcinoma, 83.3% (5/6 cases) for solid tubular carcinoma, 77.4% (24/31 cases) for scirrhous carcinoma, and 0% (0/1 case) for mucinous carcinoma. There was a significant correlation between the cytology specimens and tissue sections with respect to accuracy in the analysis of HER2 protein status [correlation coefficient, rs, was 0.89 (P<0.01, n=58)] (Fig. 4) .
HER2 amplification. HER2 amplification data for tissue sections are shown in Table V . Twenty-five cases (43.1%) showed gene amplification, and 33 cases showed no amplification. Among cases with amplification of HER2, 2 cases had a score of A, 15 cases had a score of B, 5 cases had a score of C, and 11 cases had a score of D. In 3 of the 11 cases with score D, low HER2 amplification was confirmed with the Chr17 cen probe. Among tissue sections, the percentage of cases with HER2 amplification relative to the protein score was 10.0% for score 0 (2/20 cases), 12.5% for score 1+ (1/8 cases), 66.7% for score 2+ (6/9 cases), and 76.2% for score 3+ (16/21 cases) ( Table II) . The HER2 scores on FNAC specimens are shown in Table V . Twentyfive cases (43.1%) showed amplification of HER2, and 33 cases showed no amplification. Among cases with gene amplification, 0 cases had score A, 17 had score B, 4 had score C, and 12 had score D. Of the 12 cases with score D, 4 were confirmed to have low HER2 amplification with the Chr17 cen probe. On FNAC specimens, the percentage of cases with amplification of HER2 relative to the protein score was 0% (0/21 cases) for score 0, 25.0% (1/4 cases) for score 1+, 58.8% (10/17 cases) for score 2+, and 87.5% (14/16 cases) for score 3+ (Table III) . With respect to histologic types, concordance was 85.0% (17/20 cases) in papillotubular carcinoma, 83.3% (5/6 cases) in solid tubular carcinoma, 87.1% (27/31 cases) in scirrhous carcinoma, and 100.0% (1/1 case) in mucinous carcinoma. The sensitivity, specificity and accuracy for detection of HER2 gene amplification in cytology specimens in comparison to tissue sections were 84.0% (21/25 cases), 87.9% (29/33 cases), and 86.2% (50/58 cases), respectively (Table VI) . Our results suggest that FNAC specimens can be used for detection of HER2 amplification and overexpression in invasive breast cancer.
Discussion
Trastuzumab and trastuzumab with chemotherapy are more effective treatment strategies for cancers with HER2 amplification than for those without amplification (1) (2) (3) (4) . For some studies, we found good concordance between CISH and FISH (15) (16) (17) (18) (19) (20) . The main difficulty in adopting FISH for clinical diagnostics is the need for fluorescence microscopy, which is not done in most routine diagnostic laboratories. Moreover, because fluorescence signals fade within a few weeks, hybridization results must be recorded with expensive digital cameras. To address these practical limitations, we used the CISH method because the probe can be detected with a simple IHC-like peroxidase reaction.
Although CISH-based analysis of HER2 gene amplification has been reported for tissue sections of breast cancer (16, 17, 21) , analysis of HER2 amplification in cytology specimens has not been reported. The aim of the present study was to determine whether FNAC specimens can be used to examine HER2 gene amplification, and we thus compared the data from tissue sections and FNAC specimens.
We used the Spot-Light CISH Detection kit for analysis of cytology specimens. However, we were unable to obtain adequate signals and had to modify the manufacturer's protocol. These changes included a second fixation in 10% neutral buffered formalin for 1 min followed by 4% paraformaldehyde for 15 min, denaturation at 80˚C for 3 min, then 90˚C for 3 min, and a washing in a stringent solution sodium citrate at 72˚C for 5 min followed by a washing in a 1:10 dilution of sodium citrate at 50-55˚C for 5 min. With this modified protocol, we were able to obtain adequate signals on the cytology specimens.
The HER2 gene amplification rate is high (43.2%) on FNAC specimens and tissue sections, as the relatively large size of tumors in the present study would suggest that they were examined for hormone receptor expression. Accordance between results in FNAC and tissue specimens did not differ among histologic types. With respect to HER2 protein expression, all FNAC specimens with a score of 0 or 1+ (25 cases) had score of 0 or 1+ on tissue sections. Most (81.3%, 13/16 cases) FNAC specimens with protein scores of 3+ also had a score of 3+ on tissue sections, and the remaining 3 cases with a HER2 protein score of 3+ showed amplification of the HER2 gene on tissue sections. However, only 35.3% (6/17 cases) of FNAC specimens with a HER2 protein score of 2+ had the same score on tissue sections. These findings suggest that for cases with HER2 protein scores of 0, 1+, or 3+, FNAC specimens may be used instead of tissue sections without a loss of accuracy. However, the low accordance between FNAC specimens and tissue sections for cases with a score of 2+ indicates that FNAC cannot be substituted for tissue sections under these conditions.
With respect to HER2 gene amplification, the sensitivity, specificity, and accuracy for the detection of HER2 gene amplification in FNAC specimens compared with that in tissue sections were 84.0% (21/25 cases), 87.9% (29/33 cases), and 86.2% (50/58 cases), respectively. Four of the 25 cases with HER2 gene amplification on tissue sections were negative for amplification on FNAC specimens. We believe that these false-negative results may have been due to sampling errors. In other words, the cells were not aspirated from the cancer nest. Increasing the quality of FNAC specimen by aspirating from several areas of the cancer may improve the accuracy of detection by FNAC. There were 4 of 33 cases that were negative for the HER2 gene on tissue sections were positive for amplification on FNAC specimens. FNAC specimens from these 4 false-positive cases had an amplification score of D, and FNAC specimens had to be examined with a Chr17 cen probe. Of these 4 cases, 2 had a score of D on both FNAC specimens and tissue sections.
Because FNAC is a minimally invasive technique for obtaining tissue samples, we are able to easily obtain multiple specimens. With a combination of tests for some FNAC specimens, we can correctly assess HER2 status during the pretreatment stage. Moreover, if the core needle biopsy specimen is small or if cancer cells are crushed, it is beneficial to assess the HER2 status with FNAC specimens.
